Alcon Inc.

easyJet plc

RELX PLC

UBS has <a href="https://www.cnbc.com/2026/01/27/ubs-eyes-over-50percent-upside-from-these-european-stocks-.html">named</a>&nbsp;five European stocks that investors should watch ahead of the upcoming earnings season. Three of the picks are small- or mid-cap companies, while the other two are large caps. UBS sees upside of more than 50% for all five names.

UBS shares top European picks ahead of earnings season, incl. three small caps

Once Upon a Farm, an organic baby food maker cofounded by actress Jennifer Garner, has announced plans for an IPO to raise up to $209 million. The company <a href="https://www.sec.gov/Archives/edgar/data/1696556/000119312525222798/d832753ds1.htm">filed</a>&nbsp;for the offering in September last year but <a href="https://www.linkedin.com/feed/update/urn:li:activity:7398082579863724032/">postponed</a> the listing after a U.S. government shutdown disrupted the planned timeline.

Jennifer Garner’s Once Upon a Farm announces IPO to raise up to $209 million

TRX Gold Corporation

Motley Fool highlights miner TRX Gold as a 'leveraged play on gold prices'

Corvus Pharmaceuticals, Inc.

Trinseo PLC

Freedom Broker has named the two stocks from the smid-cap-tracking Russell 2000 index with best and worst performance from January 9 through January 22. The former was recorded by Corvus Pharmaceuticals, which is developing a drug for atopic dermatitis, while the worst performer was Trinseo, a producer of specialty materials for the construction and automotive industries.

Freedom names biggest small-cap winner and loser in last two weeks

The Russell 2000, which tracks smid-cap stocks, hit <a href="https://www.bloomberg.com/news/articles/2026-01-22/small-caps-headed-for-longest-win-streak-over-s-p-500-since-1996">another record high</a> on Thursday, January 22, for the eighth time since the start of 2026. It also outperformed the U.S. broad-market benchmark, the S&amp;P 500, for the 14th consecutive session. That marks the Russell 2000’s longest winning streak versus large caps since May 1996, the <i>Wall Street Journal</i> <a href="https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-01-22-2026/card/russell-2000-winning-streak-is-its-longest-in-nearly-30-years-RnuZ0lfDDkkDHzTUUXXs?mod=lctimeline_finance">notes</a>. This is just the beginning, according to investment bank <a href="https://www.bloomberg.com/news/articles/2026-01-22/small-caps-headed-for-longest-win-streak-over-s-p-500-since-1996">BTIG</a>.

Russell 2000 sets eighth record high in 2026. How long will the rally go?

The company's CEO noted the 'wow effect on the stock'

Macron's sunglasses at Davos send shares of Italy's iVision skyrocketing

Biohaven Ltd.

Investment bank RBC Capital Markets <a href="https://www.cnbc.com/2026/01/21/this-biotech-stock-has-plummeted-over-the-past-year-rbc-says-it-sees-a-big-gain-ahead.html">upgraded</a>&nbsp;to "outperform"&nbsp;its rating on shares of Biohaven Ltd, a small cap developer of drugs for epilepsy and kidney disease. The upgrade follows new clinical data that, in RBC’s view, reduces development risk and improves the risk-reward profile. The bank now sees potential for the stock to rise 70% from current levels.

RBC Capital upgrades TP and rating on small-cap biotech Biohaven, seeing 70% upside

Ubisoft Entertainment SA

Ubisoft shares plummeted to historic lows

Assassin's Creed creator loses third of market value in a day amid major reorg

MAIA Biotechnology, Inc.

Shares of <a href="https://finance.yahoo.com/quote/MAIA/">MAIA Biotechnology</a>, a micro-cap developer of a cancer drug designed to “<a href="https://oninvest.com/article/obmanut-rakovuu-kletku-pocemu-akciam-maia-prognoziruut-semikratnyj-rost">trick</a>” tumor cells, surged 26% on Monday, January 20, to their highest level since May 2025. The company’s lead therapy is moving closer to potential regulatory approval in the U.S., which MAIA <a href="https://ir.maiabiotech.com/news-events/press-releases/detail/166/maia-biotechnology-advances-ateganosine-cancer-treatment">described</a>&nbsp;as a “clear value-creation inflection point” for shareholders.

Maria Dranishnikova

Writes about:

Articles: 713